We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 4

Figure 4. From: Outcomes of Living and Deceased Donor Liver Transplant Recipients with Hepatocellular Carcinoma: Results of the A2ALL Cohort.

Unadjusted probability of recurrence-free survival by time since LDLT or DDLT for (a) all HCC patients and (b) HCC patients in the MELD era.

L. M. Kulik, et al. Am J Transplant. ;12(11):2997-3007.
2.
Figure 3

Figure 3. From: Outcomes of Living and Deceased Donor Liver Transplant Recipients with Hepatocellular Carcinoma: Results of the A2ALL Cohort.

Unadjusted probability of patient survival by time since LDLT or DDLT for (a) all HCC patients and (b) HCC patients in the MELD era.

L. M. Kulik, et al. Am J Transplant. ;12(11):2997-3007.
3.
Figure 1

Figure 1. From: Outcomes of Living and Deceased Donor Liver Transplant Recipients with Hepatocellular Carcinoma: Results of the A2ALL Cohort.

Cumulative probability over time of LDLT, DDLT, remaining alive on the waitlist, and death without transplant, from the first living donor evaluation (based on the cumulative incidence function) for (a) HCC patients in the Pre-MELD Era and (b) HCC patients in the MELD era.

L. M. Kulik, et al. Am J Transplant. ;12(11):2997-3007.
4.
Figure 2

Figure 2. From: Outcomes of Living and Deceased Donor Liver Transplant Recipients with Hepatocellular Carcinoma: Results of the A2ALL Cohort.

Probability of freedom from HCC recurrence by time since LDLT or DDLT for (a) all HCC patients (unadjusted), (b) HCC patients in the MELD era (unadjusted), and (c) all HCC patients (adjusted based on a Cox regression model, with both LDLT and DDLT groups presented for the overall average baseline characteristic values of two liver nodules, largest nodule 3.5 cm, and without vascular invasion).

L. M. Kulik, et al. Am J Transplant. ;12(11):2997-3007.
5.
Figure 5

Figure 5. From: Outcomes of Living and Deceased Donor Liver Transplant Recipients with Hepatocellular Carcinoma: Results of the A2ALL Cohort.

Adjusted probability of patient mortality by time from first living donor evaluation, for (a) all HCC patients and (b) HCC patients in the MELD era, both based on Cox regression models with both LDLT and DDLT groups presented for the average baseline characteristic values (55 years old, beyond Milan, AFP=10, lab MELD=12, and without ablation).

L. M. Kulik, et al. Am J Transplant. ;12(11):2997-3007.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk